Efficacy of Fluvastatin in Patients with Hypercholesterolemia / 대한내분비학회지
Journal of Korean Society of Endocrinology
; : 75-84, 1996.
Article
in Korean
| WPRIM (Western Pacific)
| ID: wpr-765533
Responsible library:
WPRO
ABSTRACT
Background:
Fluvastatin is the first entirely synthetic 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA) reductase inhibitor. Clinical data indicate that this agent exhibits the proven efficacy of its class and also has some theoretical advantages in safety for long-term use because of its unique pharmacololgic property consistent with hepatoselectivity(i.e., low systemic exposure). This study is to evaluate efficacy and safety of fluvastatin in hypercholesterolemic patients in Korea.Methods:
An open clinical trial with fluvastatin was conducted in 31 subjects who continued to have high blood cholesterol levels of 6.21 mmol/L(240 mg/dl) or greater after 1 month of lipid-lowering diet plus single blind placebo period. Fluvastatin was administered for 8 weeks with the initial dose of 20 mg per day and if serum cholesterol levels did not fall below 5.20 mmol/L(200 mg/dl) after 4 weeks the dose was increased to 40 mg per day for the second 4 weeks. On each visit every 4 weeks they underwent interview and laboratory tests about side effects and tolerability.Results:
The mean % changes in plasma total cholesterol and LDL-cholesterol from baseline were
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Oxidoreductases
/
Plasma
/
Sleep Stages
/
Triglycerides
/
Cholesterol
/
Creatine Kinase
/
Diet
/
Hypercholesterolemia
/
Korea
Type of study:
Controlled clinical trial
Limits:
Humans
Country/Region as subject:
Asia
Language:
Korean
Journal:
Journal of Korean Society of Endocrinology
Year:
1996
Document type:
Article